Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
NCT03315871Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2018
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa in prostate cancer (PCa), sponsored by National Cancer Institute. Started Mar 2018; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03315871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315871.